851728-91-1

Basic information

• Product Name: 2,2-DIFLUORO-N-(2-HYDROXYETHYL)PROPIONAMIDE
• Synonyms: 2,2-DIFLUORO-N-(2-HYDROXYETHYL)PROPIONAMIDE;2,2-DIFLUORO-N-(2-HYDROXYETHYL)PROPANAMIDE
• CAS NO: 851728-91-1
• Molecular Formula: C₅H₉F₂NO₂
• Molecular Weight: 153.1272664
• Mol File: 851728-91-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 85°C/0.2mm
• Appearance: /
• CAS DataBase Reference: 2,2-DIFLUORO-N-(2-HYDROXYETHYL)PROPIONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-DIFLUORO-N-(2-HYDROXYETHYL)PROPIONAMIDE(851728-91-1)
• EPA Substance Registry System: 2,2-DIFLUORO-N-(2-HYDROXYETHYL)PROPIONAMIDE(851728-91-1)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 851728-91-1(Hazardous Substances Data)

Usage

Molecular weight

160.12 g/mol

Functional groups

Amide, fluorine atoms, hydroxyethyl group

Appearance

Colorless or off-white crystalline solid

Melting point

63-65°C

Boiling point

Not readily available due to decomposition at high temperatures

Solubility

Slightly soluble in water, soluble in organic solvents like ethanol and methanol

Reactivity

Reacts with strong bases, nucleophiles, and electrophiles due to the presence of the amide group and fluorine atoms

Uses

Intermediate for the synthesis of pharmaceutical and agrochemical products, building block for organic synthesis, valuable tool for medicinal chemistry and drug development, and production of fine chemicals and specialty materials.

Upstream product

• 28781-85-3 ethyl 2,2-difluoropropanoate 
• 141-43-5 ethanolamine 

Downstream Products

• 406-99-5 2-(2,2-difluoro-propylamino)-ethanol 

Relevant articles and documents

Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)- 6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8-(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity

We report the design, synthesis, and structure-activity relationships of novel bicyclic lactam-based cannabinoid type 1 (CB1) receptor antagonists. Members of these series are potent, selective antagonists in in vitro/in vivo efficacy models of CB1 antagonism and exhibit robust oral activity in rodent models of food intake. These efforts led to the identification of 19d, which has been advanced to human clinical trials for weight management.

Bicyclic pyrazolyl and imidazolyl compounds and uses thereof

Compounds of Formula (I) are described herein. The compounds have been shown to act as cannabinoid receptor ligands and are therefore useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals.